Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03323710
Other study ID # PS-001
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date September 2018
Est. completion date December 2019

Study information

Verified date January 2019
Source Military Institute of Medicine, Poland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims to assess antineoplastic efficacy, safety, influence on quality of life and disease-related stress of propranolol taken in combination with sunitinib in previously untreated metastatic renal cell carcinoma


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2019
Est. primary completion date December 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

Patients are eligible to be included in the study only if they meet all of the following criteria:

1. Histological diagnosis of clear-cell renal cell carcinoma (RCC) or mixed-type RCC with more than 60% of clear-cell component.

2. Diagnosis of stage IV RCC (primary metastatic or recurrence after surgical procedure).

3. Prior nephrectomy (complete or partial).

4. Presence of measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1.

5. Karnofsky performance status score of 80-100%.

6. Favourable- or intermediate-risk according to Memorial Sloan Kettering Cancer Center criteria.

7. Adequate organ function, including the following:

1. hepatic: total bilirubin = 2 times the upper limit of normal (excluding patients with Gilbert syndrome), aspartate aminotransferase and alanine aminotransferase = 5 times the upper limit of normal,

2. renal: serum creatinine = 2 times the upper limit of normal,

3. bone marrow: absolute neutrophil count = 1500/mm3, platelets = 100000/mm3, hemoglobin = 9.5 g/dl.

8. Normal thyroid function (natural or with supplementation of thyroid hormones) defined as thyroid-stimulating hormone within limits of normal.

9. Age eighteen years or older on the day of consent.

10. Written informed consent prior to study entry.

Exclusion Criteria:

Patients will be excluded from the study if they meet any of the following criteria:

1. Prior systemic pharmacotherapy of RCC.

2. Treatment with propranolol within 6 months of study entry.

3. Metastases in central nervous system (patients who had central nervous system metastases that were surgically resected and/or treated with radiotherapy in the past and now are without neurological symptoms, are allowed on protocol).

4. Female patients who are pregnant or breast feeding or adults of reproductive potential who are not using effective birth control methods.

5. Presence of other malignancies (patients with carcinoma in situ of the cervix or basal cell carcinoma of the skin are allowed on protocol).

6. Presence of any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:

1. heart failure of New York Heart Association Class III or IV, significant cardiac arrhythmia or any other clinically significant cardiovascular disease,

2. unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of entering the study,

3. severely impaired respiration as defined as O2 saturation that is = 90% at rest on room air,

4. uncontrolled diabetes as defined by fasting serum glucose > 1.5 times the upper limit of normal,

5. ejection fraction less than 40% (measured at echocardiography),

6. significant liver disease such as cirrhosis, active hepatitis or chronic persistent hepatitis,

7. active (acute or chronic) infections requiring antimicrobial intervention.

7. Concomitant treatment with:

1. chronic, systemic corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowed,

2. strong CYP3A4 inducers/inhibitors: carbamazepine, phenytoin, rifabutin, rifampin, nafcillin, phenobarbital, St John's wort, itraconazole, ketoconazole, erythromycin, clarithromycin, nefazodone.

8. Known allergy/sensitivity to sunitinib and/or propranolol.

9. Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

10. Immunization with attenuated live vaccines within 30 days of study entry.

11. Human immunodeficiency virus sero-positivity at the study entry or in the past.

12. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of sunitinib and/or propranolol (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).

13. Presence of active, bleeding diathesis.

14. Major surgery (defined as requiring general anesthesia) and/or significant traumatic injury (requiring > 28 days to heal) within 28 days of the study entry; presence of side effects due to any surgery or probable requirement of major surgery during the course of the study.

15. Present contraindications to propranolol, that include: bronchial asthma, prolonged fasting, acidosis, hypotension (systolic blood pressure less than 90 mmHg, diastolic blood pressure less than 60 mmHg), severe peripheral arterial circulatory disturbance, cardiogenic shock, bradycardia, Prinzmetal's angina, uncontrolled heart failure, second or third degree heart block, untreated phaeochromocytoma, sick sinus syndrome.

16. Inability or unwillingness of subject or legal guardian/representative to give written informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Propranolol
Propranolol will be administered orally at a starting dose of 40 mg (one tablet) two times a day (total daily dose of 80 mg). In case of acceptable safety profile, the dose may be increased to 80 mg (two tablets) two times a day (total daily dose of 160 mg) or farther to 80 mg (two tablets) three times a day (total daily dose of 240 mg).
Sunitinib
Sunitinib will be administered orally at a starting dose of 50 mg once daily, for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks.The schedule may be changed to 2 weeks on / 1 week off (schedule 2/1) and a daily dose may be reduced to 37.5 mg or 25 mg to decrease the level of toxic side effects.

Locations

Country Name City State
Poland Military Institute of Medicine Warsaw Mazowieckie

Sponsors (1)

Lead Sponsor Collaborator
Military Institute of Medicine, Poland

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (ORR) Objective Response Rate (ORR) is defined as the percentage of patients who have achieved partial response (PR) or complete response (CR) according to the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. Up to 18 months
Secondary Overall Survival (OS) Overall Survival (OS) is defined as the time from treatment initiation to death from any cause. Up to 18 months
Secondary Progression-free Survival (PFS) Progression-free Survival (PFS) is defined as the time from treatment initiation to the first date of objectively determined progressive disease (PD) according to the RECIST v1.1 or death from any cause, whichever occurred first. Up to 18 months
Secondary Disease Control Rate (DCR) Disease Control Rate (DCR) is defined as the percentage of patients who have achieved partial response (PR), complete response (CR) or stable disease (SD) according to the RECIST v1.1. Up to 18 months
Secondary Safety profile as assessed by Common Terminology Criteria for Adverse Events v4.03 summarized by type, frequency, and severity. Safety profile as assessed by Common Terminology Criteria for Adverse Events v4.03 summarized by type, frequency, and severity. Up to 18 months
Secondary Health-related Quality of Life (QoL) Change from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) v3.
The EORTC QLQ-C30 includes five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the scales and single-item measures range from 0 to 100. High score for a functional scale represents a high / healthy level of functioning. High score for the global health status / QoL represents a high QoL. High score for a symptom scale / item represents a high level of symptomatology / problems. Scoring these scales include the following steps:
Estimate the average of the items that contribute to the scale (the raw score).
Use the linear transformation to standardise the raw score, so that scores range from 0 to 100; a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms.
Up to 18 months
Secondary Health-related Quality of Life (QoL) Change from baseline in the Functional Assessment of Cancer Therapy-Kidney Symptom Index - 15. Up to 18 months
Secondary Disease-related Stress (DRS) Change from baseline in the 10-point Perceived Stress Scale (PSS).
The PSS is a validated psychological tool for assessing the perception of stress. Patient responses to all of the 10 questions present in the PSS questionnaire range from 0 to 4. To obtain a total result:
Reverse scores for questions 4, 5, 7, and 8.
Add up scores for each question to get a total result. Individual total scores range from 0 to 40. Higher scores indicate higher perceived stress.
Up to 18 months
Secondary Tumour tissue and serum biomarkers status Descriptive statistics of selected biomarkers from analysis of patient samples. Up to 18 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04987203 - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Phase 3
Recruiting NCT06391879 - Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Completed NCT02853344 - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Phase 2
Terminated NCT04088500 - A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma Phase 2
Completed NCT05070637 - Circulating Tumor Cell Reducing No-touch Nephrectomy N/A
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Not yet recruiting NCT06049030 - A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT01358721 - Phase I Biomarker Study (BMS-936558) Phase 1
Active, not recruiting NCT04503148 - Anesthesia and Cancer Study: Renal Cell Carcinoma N/A
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Not yet recruiting NCT05808608 - A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma Phase 1/Phase 2
Completed NCT03052504 - Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy
Not yet recruiting NCT02787915 - DC1s-CTL Cellular Therapy for Renal Cell Carcinoma Phase 1/Phase 2